Mucinex Acquisition Nothing to Sneeze At | Adweek Mucinex Acquisition Nothing to Sneeze At | Adweek
Advertisement

Mucinex Acquisition Nothing to Sneeze At

Advertisement

Reckitt Benckiser's increased marketing spend and acquisition of Adams Respiratory made for some healthy earnings for the first half of the year. RB reported that its net revenues increased 11% ($6.1 billion). Growth was driven by higher investment in RB's 17 Powerbrands, including Lysol, Calgon and Woolite, as well as the successful rollout of Airwick Symphonia.

The company noted that its marketing investment was significantly higher for the period. Pure media investment increased 25% to a level of 13.5% of net revenues. This is approximately $828 million.

"Reckitt Benckiser had a very good first half with 11% net revenue growth. Growth was driven by higher investment in our Powerbrands and successful innovations such as Finish Max in 1, Airwick Symphonia and Nurofen Express," said RB's CEO Bart Becht in a statement.

Its North American and Australian business made up 25% of its net revenues. Among the brands that performed strongly in the U.S. was Mucinex. RB acquired parent company Adams Respiratory in December. It contributed $131 million for the first half of the year. This represented a growth rate of 33% compared to the year prior.

Food grew strongly due to the consumer brands of French's Yellow Mustard, French's Fried Onions and Frank's Red Hot sauce.

RB also announced a flurry of new product launches, such as Lysol Dual Action disinfecting wipes (a new disinfecting wipe with two different sides, one for scrubbing to remove tough residues, and one for wiping for a completely clean surface) and Airwick Aqua Essences (a range of clean, refreshing fragrances based on water-borne plants for 'a more natural fragrance experience').